Top Menu

  • For Healthcare Providers
  • Jazz Pharmaceuticals Corporate Site
Home

Main navigation

  • Connect with us
  • Product information
  • About narcolepsy
  • About IH
  • About XYWAV

Fields with (*) are mandatory

Organization ZIP
back-to-top
logo

Footer

  • Privacy Statement
  • Contact Us
  • Terms of Use
  • Jazz Pharmaceuticals
  • Your Privacy Choices

This site is intended for US residents only.

© 2025 Jazz Pharmaceuticals plc or its subsidiaries

US-XYW-2500194 Rev1125

Collapsed ISI

IMPORTANT SAFETY INFORMATION

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.

  • Central Nervous System Depression

    XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses. Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving CNS stimulants.

  • Abuse and Misuse

    The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.

Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS.